SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,102.40+0.22%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%
Benzinga

Benzinga Editor

Articles by

Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability ---- Study initiation on track, with
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved